Ingredient [Reference] | Trial | Outcomes | Supplier/product code | g/mix |
---|---|---|---|---|
Wheat dextrin [43] | Intensive care unit patients (~ 65 years) 10–22 g/day × 2–5 weeks | Increase in Firmicutes, butyrate-producing bacteria (Eubacterium hallii, Eubacterium rectale, Roseburia intestinalis, Clostridia cluster XIVa), starch degrading bacteria (Ruminococcus bromii, Ruminococcus obeum, Sporobacter terminitidis), Fecalibacterium prausnitzii, Bifidobacterium spp., & SCFA levels | Ingredion/Nutriose FB 06 | 3 |
Resistant starch [24] | Rats 10%–20 weeks | Reduced incidence of colon carcinogenesis possibly through an increase in butyrate | Ingredion/Novelose 330 | 10 |
Polydextrose [3] | Healthy males (20–40 years) 21 g/day × 21 days | Increase in Faecalibacterium, Phascolarctobacterium and Dialister | Danisco/Litesse | 3 |
Soluble corn fiber [3] | Healthy males (20–40 years) 21 g/day × 21 days | Increase in Faecalibacterium, Phascolarctobacterium, Dialister, Roseburia and Lactobacillus | Tate and Lyle/ SCF 22–5421/Promitor soluble fiber 85 | 3 |
Galactooligo-saccharide [4] | Healthy humans (19–50 years) 5–10 g/day × 16 weeks | Bifidogenic, increase in Fecalibacterium prausnitzii and Actinobacteria and reduction in Bacteroides | Friesland Campina/Vivinal GOS | 2 |
Total max daily supplement | 21 |